GlaxoSmithKline
When top and bottom line growth are proving elusive for any company, a period of rationalisation and restructuring often follows. Thats the current situation at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), where sales and profit growth have stalled in recent years and, as such, the company is considering a spin-off of its star HIV division, ViiV Healthcare. This could create shareholder value in a similar way to that which has taken place at Reckitt Benckiser and Indivior, with the combined market capitalisations of the two companies now being higher than when they were together.
And, with GlaxoSmithKline seemingly having considerable scope to make significant changes over the medium term, its slow-growth profile may not hold back its share price. As a result, now could be a great time to buy a slice of it.
BTG
Although the pharmaceutical sector is often viewed as relatively defensive, BTG (LSE: BTG) remains a high-risk stock. Thats because its bottom line is relatively volatile, although encouragingly for its investors the next two years are set to see it grow by around 93%, which would clearly be a superb result and help to improve investor sentiment.
In fact, investor sentiment in BTG has been somewhat lacklustre in 2015, with the companys share price falling by 1% since the turn of the year. This, then, could present an excellent opportunity to buy in before everyone else does and, while BTG has a price to earnings (P/E) ratio of 37, it still seems to offer good value for money when its growth potential is factored in.
Hikma
Surprisingly, shares in Hikma (LSE: HIK) have risen by 10% since the turn of the year. That was unexpected because the company is forecast to post a decline in earnings in the current year of 9%, which should (in theory) cause investor sentiment to weaken rather than improve. However, Hikmas promotion to the FTSE 100 may have caused a surge in buying by tracker funds, which may explain why its shares have been bid up.
Looking ahead, Hikma is expected to bounce back next year with bottom line growth of 18%. And, when this is combined with its P/E ratio of 23.3, it equates to a price to earnings growth (PEG) ratio of just 1.2, which indicates that Hikmas share price could move significantly higher over the medium to long term.
Of course, Hikma, GlaxoSmithKline and BTG aren’t the only companies that could boost your portfolio returns. However, finding the best stocks at the lowest prices in any sector can be challenging when you lack the time to scour the index for them.
That’s why the analysts at The Motley Fool have written a free and without obligation guide called 10 Steps To Making A Million In The Market.
It’s a step-by-step guide that could make a real difference to your financial future and allow you to retire early, pay off your mortgage, or even build a seven-figure portfolio.
Click here to get your free and without obligation copy – it’s well-worth a read!
Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended BTG, GlaxoSmithKline and Hikma Pharmaceuticals. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.